These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12580954)

  • 1. Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients.
    Galimberti S; Morabito F; Guerrini F; Palumbo GA; Azzará A; Martino M; Benedetti E; Di Raimondo F; Petrini M
    Br J Haematol; 2003 Feb; 120(3):405-12. PubMed ID: 12580954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests.
    Ladetto M; Omedè P; Sametti S; Donovan JW; Astolfi M; Drandi D; Volpato F; Giaccone L; Giaretta F; Palumbo A; Bruno B; Pileri A; Gribben JG; Boccadoro M
    Exp Hematol; 2002 Jun; 30(6):529-36. PubMed ID: 12063019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A negative-selection strategy for depleting myeloma cells from patients' BM and/or leukapheresis blood.
    Louis SA; Zapf R; Clarke E; Thomas TE; Sutherland HJ
    Cytotherapy; 2001; 3(6):489-504. PubMed ID: 11953033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Significance of
    Cheng P; Guan J; Zhou Y; Wang QX; Wang LL; Zhang T; Cheng H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):164-170. PubMed ID: 38387916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma.
    Putkonen M; Kairisto V; Juvonen V; Pelliniemi TT; Rauhala A; Itälä-Remes M; Remes K
    Eur J Haematol; 2010 Nov; 85(5):416-23. PubMed ID: 20722702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma.
    Galimberti S; Marasca R; Caracciolo F; Fazzi R; Papineschi F; Benedetti E; Guerrini F; Morabito F; Oliva E; Di Renzo N; Federico M; Petrini M; Torelli G;
    Bone Marrow Transplant; 2002 Apr; 29(7):581-7. PubMed ID: 11979307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts.
    Vescio RA; Han EJ; Schiller GJ; Lee JC; Wu CH; Cao J; Shin J; Kim A; Lichtenstein AK; Berenson JR
    Bone Marrow Transplant; 1996 Jul; 18(1):103-10. PubMed ID: 8832002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    López-Pérez R; García-Sanz R; González D; Balanzategui A; Chillón MC; Alaejos I; Mateos MV; Caballero MD; Corral M; Orfão A; González M; San Miguel JF
    Bone Marrow Transplant; 2001 Oct; 28(7):665-72. PubMed ID: 11704789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies.
    Moos M; Schulz R; Cremer F; Sucker C; Schmohl D; Döhner H; Goldschmidt H; Haas R; Hunstein W
    Stem Cells; 1995 Dec; 13 Suppl 3():42-51. PubMed ID: 8747988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting system.
    Voena C; Locatelli G; Castellino C; Omedè P; Ladetto M; Zappone E; Milani R; Perfetti V; Boccadoro M; Pileri A; Lusso P; Villa C; Malnati M; Corradini P
    Br J Haematol; 2002 Jun; 117(3):642-5. PubMed ID: 12028036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial.
    Stewart AK; Vescio R; Schiller G; Ballester O; Noga S; Rugo H; Freytes C; Stadtmauer E; Tarantolo S; Sahebi F; Stiff P; Meharchard J; Schlossman R; Brown R; Tully H; Benyunes M; Jacobs C; Berenson R; White M; DiPersio J; Anderson KC; Berenson J
    J Clin Oncol; 2001 Sep; 19(17):3771-9. PubMed ID: 11533101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral blood monoclonal B-cells predict the event free survival in multiple myeloma.
    Mitterer M; Lanthaler AJ; Schnabel B; Svaldi M; Oduncu F; Coser P; Emmerich B; Huemer H; Straka C
    Leuk Lymphoma; 2001 Apr; 41(3-4):387-95. PubMed ID: 11378552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests.
    Henry JM; Sykes PJ; Brisco MJ; To LB; Juttner CA; Morley AA
    Br J Haematol; 1996 Mar; 92(3):614-9. PubMed ID: 8616025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation.
    Martinelli G; Terragna C; Zamagni E; Ronconi S; Tosi P; Lemoli R; Bandini G; Testoni N; Amabile M; Ottaviani E; Buonamici S; Soverini S; Montefusco V; de Vivo A; Bonifazi F; Tura S; Cavo M
    Haematologica; 2000 Sep; 85(9):930-4. PubMed ID: 10980631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study.
    Bourhis JH; Bouko Y; Koscielny S; Bakkus M; Greinix H; Derigs G; Salles G; Feremans W; Apperley J; Samson D; Björkstrand B; Niederwieser D; Gahrton G; Pico JL; Goldschmidt H;
    Haematologica; 2007 Aug; 92(8):1083-90. PubMed ID: 17640853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma.
    Davies FE; Forsyth PD; Rawstron AC; Owen RG; Pratt G; Evans PA; Richards SJ; Drayson M; Smith GM; Selby PJ; Child JA; Morgan GJ
    Br J Haematol; 2001 Mar; 112(3):814-9. PubMed ID: 11260088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow up of sequential mobilisation and autologous transplantation with CD34-selected cells in multiple myeloma: a multimodality approach.
    Horvath N; Hahn U; Joshua D; Dyson P; Gibson J; Stevens J; Rawling T; Barrow L; Brown R; Stephens S; Gower G; Norman J; Mills B; To LB
    Intern Med J; 2004 Apr; 34(4):167-75. PubMed ID: 15086696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human herpesvirus 8 (KSHV) contamination of peripheral blood and autograft products from multiple myeloma patients.
    Vescio RA; Wu CH; Zheng L; Sheen D; Ma H; Liu J; Stewart AK; Ballester O; Noga SJ; Rugo H; Freytes C; Stadtmauer E; Sahebi F; Tarantolo S; Stiff P; Schiller GJ; White M; Jacobs C; DiPersio J; Anderson KC; Berenson JR
    Bone Marrow Transplant; 2000 Jan; 25(2):153-60. PubMed ID: 10673673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients.
    Ladetto M; Sametti S; Donovan JW; Ferrero D; Astolfi M; Mitterer M; Ricca I; Drandi D; Corradini P; Coser P; Pileri A; Gribben JG; Tarella C
    Exp Hematol; 2001 Feb; 29(2):183-93. PubMed ID: 11166457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.